[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354051-105":59,"doc-detail-354051-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","jph3-facilitates-cisplatin-resistance-in-anaplastic-thyroid-cancer-via-activation-of-the-jakstat-signaling-pathway","JPH3 Facilitates Cisplatin Resistance in Anaplastic Thyroid Cancer via Activation of the JAK–STAT Signaling Pathway","","Background: Junctophilin 3 (JPH3) is reported as a tumor suppressor in several cancers, yet its function in anaplastic thyroid cancer (ATC) remains unclear. Methods: JPH3 expression in ATC was assessed using bioinformatics and validated by Western blot. In vitro and in vivo assays evaluated ATC phenotypes, while molecular studies clarified the mechanism. Results: JPH3 was elevated in thyroid cancer, acted as an oncogene in ATC, activated JAK–STAT signaling via COL26A1, and promoted proliferation, invasion, and migration, including DDP resistance. Conclusions: JPH3 drives ATC progression and enhances cisplatin resistance through JAK–STAT-mediated mechanisms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/jph3-facilitates-cisplatin-resistance-in-anaplastic-thyroid-cancer-via-activation-of-the-jakstat-signaling-pathway/354051/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/jph3-facilitates-cisplatin-resistance-in-anaplastic-thyroid-cancer-via-activation-of-the-jakstat-signaling-pathway/354051.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the central role of JPH3 in anaplastic thyroid cancer according to the study?","Question",{"text":112,"@type":113},"JPH3 functions as an oncogenic driver in ATC. It facilitates tumor development by activating the JAK–STAT signaling pathway and promoting malignant cellular behaviors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does JPH3 relate to cisplatin (DDP) resistance in ATC?",{"text":117,"@type":113},"JPH3 is involved in the development of DDP resistance in ATC cells. By activating JAK–STAT signaling, it induces a more malignant phenotype associated with chemoresistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links JPH3 to JAK–STAT activation in thyroid cancer?",{"text":121,"@type":113},"The study indicates that JPH3 activates the JAK–STAT signaling pathway by upregulating collagen type XXVI alpha 1 chain (COL26A1). This pathway activation then supports proliferation, invasion, and migration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354051,1790530133,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Medicine  \n|  RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>JPH3 Facilitates Cisplatin Resistance in Anaplastic Thyroid Cancer via Activation of the JAK–STAT Signaling Pathway\u003Cbr>Xiuyan Wang1 | Sha Luan2 | Lei Sun3 | Lixin Lian1 | Ming Qi1 \u003Cbr>1The Fourth Department of General Surgery, The First Hospital of Harbin, Harbin, Heilongjiang, China | 2Department of Nuclear Medicine, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China | 3Department of Critical Care Medicine, The First Hospital of Harbin, Harbin, Heilongjiang, China\u003Cbr>Correspondence: Ming Qi ([qiming@hrbsdyyy.org.cn](qiming@hrbsdyyy.org.cn); [qm1301@163.com](qm1301@163.com))\u003Cbr>Received: 7 September 2025 | Revised: 12 February 2026 | Accepted: 13 March 2026\u003Cbr>Keywords: anaplastic thyroid cancer | COL26A1 | DDP resistance | JAK–STAT signaling pathway | JPH3 | thyroid cancer |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Background: Junctophilin 3 (JPH3) acts as a tumor suppressor in several cancers; however, the role ofJPH3 in anaplastic thyroid cancer (ATC) is still unknown.\u003Cbr>Methods: Via bioinformatics prediction and verified through Western blot experiments, the expression level of JPH3 in ATC was ascertained. Subsequently, the role of JPH3 in ATC cells was validated via in vitro and in vivo experiments, and the molecular mechanism of JPH3 in ATC was further illuminated. Eventually, the mechanism of JPH3 on cisplatin (DDP)-resistant ATC cells was probed. The results indicated that JPH3 was highly expressed in thyroid cancer (TC), and the survival period of patients with high expression was significantly curtailed.\u003Cbr>Results: JPH3 was upregulated in TC tissues compared with the normal thyroid tissues. Our experiments disclosed that JPH3 acted as an oncogene in ATC cells, facilitating tumor development, and JPH3 can activate the JAK–STAT signaling pathway by upregulation of collagen type XXVI alpha 1 chain (COL26A1), and experiments attested that JPH3 promoted the proliferation, invasion, and migration of ATC cells by activating the JAK–STAT signaling pathway. Further research uncovered that JPH3 was also involved in the process of DDP resistance in ATC cells. By activating the JAK–STAT signaling pathway, JPH3 induced the malignant phenotype of DDP-resistant ATC cells.\u003Cbr>Conclusions: JPH3 functions as a potent oncogenic driver in ATC, promoting tumor proliferation, invasion, and migration through the activation of the JAK–STAT signaling pathway. This oncoprotein contributes to enhanced DDP resistance in ATC cells via JAK–STAT-mediated mechanisms, offering novel insights into the molecular basis of chemoresistance in this highly aggressive malignancy. |  |\n| 1 | Introduction | Although ATC is less common, it is characterized by a markedly low degree of differentiation and an exceptionally high |\n| Thyroid cancer (TC) represents a frequently encountered en- | level of malignancy, positioning it among the deadliest cancers |\n| docrine malignancy in clinical scenarios, with its incidence | [4] . The average overall survival for affected individuals is ap- |\n| steadily escalating due to enhancements in diagnostic meth- | proximately 3 months. Cisplatin (DDP) is a commonly employed |\n| odologies [1–3] . TC is primarily categorized into papillary thy- | chemotherapeutic agent; however, the development of DDP re- |\n| roid carcinoma (PTC) and anaplastic thyroid cancer (ATC) . | sistance is a critical factor that exacerbates the poor prognosis |\n| Xiuyan Wang and Sha Luan contributed equally to this work. |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |  |\n\nCancer Medicine, 2026; 15:e71750 1 of 13  \n[https://doi.org/10.1002/cam4.71750](https://doi.org/10.1002/cam4.71750)  \nand diminishes the survival rates of patients w","cbCaiaJCwacYVusl","https://ap.wps.com/l/cbCaiaJCwacYVusl","pdf",12806731,13,"English","# Abstract\n# Introduction\n## Background and clinical context\n## JPH3 and prior cancer evidence\n## Study rationale","[{\"question\":\"What is the central role of JPH3 in anaplastic thyroid cancer according to the study?\",\"answer\":\"JPH3 functions as an oncogenic driver in ATC. It facilitates tumor development by activating the JAK–STAT signaling pathway and promoting malignant cellular behaviors.\"},{\"question\":\"How does JPH3 relate to cisplatin (DDP) resistance in ATC?\",\"answer\":\"JPH3 is involved in the development of DDP resistance in ATC cells. By activating JAK–STAT signaling, it induces a more malignant phenotype associated with chemoresistance.\"},{\"question\":\"What mechanism links JPH3 to JAK–STAT activation in thyroid cancer?\",\"answer\":\"The study indicates that JPH3 activates the JAK–STAT signaling pathway by upregulating collagen type XXVI alpha 1 chain (COL26A1). This pathway activation then supports proliferation, invasion, and migration.\"}]","JPH3 Facilitates Cisplatin Resistance in Anaplastic Thyroid Cancer via Activation of the JAK–STAT Signaling Pathway | PDF",1790108614,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a92686aa8c4e6424efab345570bb1c5a.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f79009ac59e936c78b391096a1785fb.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/456bfafa012ee73b095aa94cfce3d33a.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e28ef9bafd8003fe34a217182b8a257f.webp",980,1287]